Shanghai Henlius hits 7-week peak after regulator's nod for new drug application

Shanghai Henlius Biotech

01/04/2026 03:43

** Shares of Shanghai Henlius Biotech Inc 2696.HK climb 5.4% to HK$73.5, their highest level since February 12

** Stock set for the biggest one-day pct gain since March 27

** Chinese biopharmaceutical research and development group says National Medical Products Administration has approved an investigational new drug (IND) application for a phase 1 clinical trial of its self-developed HLXTE-HAase02

** HLXTE-HAase02 is a novel recombinant human hyaluronidase for development of subcutaneous drug products, facilitating diffusion and absorption of drugs administered via subcutaneous injection or infusion - Co

** YTD, stock up 27.6%, Hang Seng Biotech Index .HSBIO up 7.4%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))